Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Home
About
Overview
Open Source Software
Help
History (1)
Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin.
Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin. Hypertension. 2009 Dec; 54(6):1313-20.
View in:
PubMed
subject areas
Animals
Bufanolides
Canrenone
Cardiomyopathies
Cardiotonic Agents
Cells, Cultured
Disease Models, Animal
Drug Interactions
Endomyocardial Fibrosis
Fibroblasts
Myocardium
Nephrectomy
Ouabain
Procollagen
Proline
Rats
Renal Insufficiency
Spironolactone
Tritium
Uremia